Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?

Short NJ, Ravandi F.

Haematologica. 2019 Aug;104(8):1532-1541. doi: 10.3324/haematol.2018.208454. Epub 2019 Jul 4. Review.

2.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553. [Epub ahead of print]

PMID:
31237017
3.

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ.

Ther Adv Hematol. 2019 May 19;10:2040620719849496. doi: 10.1177/2040620719849496. eCollection 2019. Review.

4.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM.

Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.

PMID:
30985931
5.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.

Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F.

Am J Hematol. 2019 Jul;94(7):E188-E190. doi: 10.1002/ajh.25490. Epub 2019 Apr 29. No abstract available.

PMID:
30977182
6.

10-day vs 5-day decitabine: equivalence cannot be concluded - Authors' reply.

Short NJ, Ravandi F.

Lancet Haematol. 2019 Apr;6(4):e178. doi: 10.1016/S2352-3026(19)30052-3. No abstract available.

PMID:
30926077
7.

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia.

Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ.

Am J Hematol. 2019 Jun;94(6):E158-E160. doi: 10.1002/ajh.25454. Epub 2019 Mar 18. No abstract available.

PMID:
30838674
8.

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia.

Short NJ, Kantarjian H, Ravandi F, Daver N.

Ther Adv Hematol. 2019 Feb 15;10:2040620719827310. doi: 10.1177/2040620719827310. eCollection 2019. Review.

9.

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Abou Dalle I, Jabbour E, Short NJ, Ravandi F.

Curr Treat Options Oncol. 2019 Jan 24;20(1):4. doi: 10.1007/s11864-019-0603-z. Review.

PMID:
30675645
10.

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F.

Lancet Haematol. 2019 Jan;6(1):e29-e37. doi: 10.1016/S2352-3026(18)30182-0. Epub 2018 Dec 10.

PMID:
30545576
11.

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.

Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F.

Cancer. 2019 Apr 1;125(7):1091-1100. doi: 10.1002/cncr.31885. Epub 2018 Dec 6.

PMID:
30521114
12.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H.

Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.

PMID:
30501869
13.

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.

Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, Radich J, Kantarjian H.

Am J Hematol. 2019 Feb;94(2):257-265. doi: 10.1002/ajh.25338. Epub 2018 Nov 26. Review.

PMID:
30394566
14.

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.

Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2019 Jan;94(1):74-79. doi: 10.1002/ajh.25318. Epub 2018 Nov 15.

PMID:
30328139
15.

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.

Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM.

Cancer. 2018 Oct 15;124(20):4044-4055. doi: 10.1002/cncr.31720. Epub 2018 Oct 11.

PMID:
30307611
16.

Acute myeloid leukaemia.

Short NJ, Rytting ME, Cortes JE.

Lancet. 2018 Aug 18;392(10147):593-606. doi: 10.1016/S0140-6736(18)31041-9. Epub 2018 Aug 2. Review.

PMID:
30078459
17.

SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Short NJ, Kantarjian H, Pui CH, Goldstone A, Jabbour E.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):439-446. doi: 10.1016/j.clml.2018.05.015. Epub 2018 May 22. Review.

PMID:
29853276
18.

Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?

Ball S, Vutthikraivit W, Maiti A, Short NJ.

Eur J Haematol. 2018 Sep;101(3):418-420. doi: 10.1111/ejh.13098. Epub 2018 Jun 22. No abstract available.

PMID:
29791043
19.

Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.

Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour E.

Clin Adv Hematol Oncol. 2018 Mar;16(3):216-223. Review.

PMID:
29742077
20.

Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.

Short NJ, Kantarjian H, Jabbour E, Ravandi F.

Curr Hematol Malig Rep. 2018 Apr;13(2):91-99. doi: 10.1007/s11899-018-0440-3. Review.

PMID:
29423571
21.

Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation.

Simkins A, Maiti A, Short NJ, Jain N, Popat U, Patel KP, Oo TH.

Hematol Oncol Stem Cell Ther. 2019 Jun;12(2):115-118. doi: 10.1016/j.hemonc.2017.09.001. Epub 2018 Jan 31.

22.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E.

Lancet Oncol. 2018 Feb;19(2):240-248. doi: 10.1016/S1470-2045(18)30011-1. Epub 2018 Jan 16.

PMID:
29352703
23.

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.

Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, Topp MS.

Am J Hematol. 2018 Mar;93(3):371-374. doi: 10.1002/ajh.24987. Epub 2017 Dec 23.

24.

Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

Short NJ, Kantarjian H, Jabbour E.

Cancer. 2017 Dec 15;123(24):4935-4936. doi: 10.1002/cncr.31036. Epub 2017 Oct 20. No abstract available.

25.

Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?

Short NJ, Kantarjian H, Jabbour E, Ravandi F.

Best Pract Res Clin Haematol. 2017 Sep;30(3):193-200. doi: 10.1016/j.beha.2017.05.001. Epub 2017 Jun 15. Review.

PMID:
29050692
26.

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.

Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):897-901. doi: 10.1016/j.clml.2017.08.101. Epub 2017 Aug 18.

PMID:
28927784
27.

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.

Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H.

JAMA Oncol. 2018 Feb 1;4(2):230-234. doi: 10.1001/jamaoncol.2017.2380.

28.

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.

Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE.

Blood. 2017 Nov 9;130(19):2084-2091. doi: 10.1182/blood-2017-07-792143. Epub 2017 Aug 23.

29.

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G.

Blood. 2017 Sep 28;130(13):1514-1522. doi: 10.1182/blood-2017-06-788497. Epub 2017 Aug 3.

30.

Yes, treatment for CML should continue indefinitely.

Short NJ, Jabbour E.

Clin Adv Hematol Oncol. 2017 Jun;15(6):489-492. No abstract available.

PMID:
28749909
31.

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.

Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E.

Leuk Lymphoma. 2018 Apr;59(4):813-820. doi: 10.1080/10428194.2017.1349907. Epub 2017 Jul 18.

32.

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.

Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H.

Cancer. 2017 Nov 15;123(22):4430-4439. doi: 10.1002/cncr.30883. Epub 2017 Jul 14.

33.

Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.

Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E.

Am J Hematol. 2017 Oct;92(10):E595-E597. doi: 10.1002/ajh.24833. Epub 2017 Jul 29. No abstract available.

34.

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F.

Br J Haematol. 2018 Aug;182(3):442-444. doi: 10.1111/bjh.14806. Epub 2017 Jun 14. No abstract available.

35.

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.

Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E.

Cancer. 2017 Oct 1;123(19):3717-3724. doi: 10.1002/cncr.30810. Epub 2017 Jun 13.

36.

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia.

Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H.

Am J Hematol. 2017 Sep;92(9):924-928. doi: 10.1002/ajh.24799. Epub 2017 Jul 19.

37.

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.

Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E.

Am J Hematol. 2017 Jun;92(6):E114-E117. doi: 10.1002/ajh.24720. Epub 2017 Apr 18. No abstract available.

38.

Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis.

Maiti A, Short NJ, Verstovsek S, Powers CA, Fullmer CA, Reyes SR, Bueso-Ramos CE.

Leuk Lymphoma. 2017 Oct;58(10):2508-2510. doi: 10.1080/10428194.2017.1295147. Epub 2017 Feb 28. No abstract available.

39.

Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.

Short NJ, Jabbour E.

Curr Oncol Rep. 2017 Jan;19(1):6. doi: 10.1007/s11912-017-0565-x. Review.

PMID:
28205134
40.

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.

Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2017 Apr;92(4):351-358. doi: 10.1002/ajh.24650. Epub 2017 Feb 13.

41.

Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.

Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E.

Am J Hematol. 2017 Mar;92(3):238-243. doi: 10.1002/ajh.24625. Epub 2017 Feb 3.

42.

Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is the best treatment for these patients.

Short NJ, Jabbour E.

Clin Adv Hematol Oncol. 2016 Nov;14(11):892-894. Review. No abstract available.

PMID:
27930640
43.

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.

Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E.

Cancer. 2017 Feb 1;123(3):459-467. doi: 10.1002/cncr.30376. Epub 2016 Oct 3.

44.

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM.

Cancer. 2017 Jan 1;123(2):294-302. doi: 10.1002/cncr.30264. Epub 2016 Sep 7.

45.

Acute Myeloid Leukemia: Past, Present, and Prospects for the Future.

Short NJ, Ravandi F.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S25-9. doi: 10.1016/j.clml.2016.02.007. Review.

PMID:
27521321
46.

Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E.

Cancer. 2016 Dec 15;122(24):3812-3820. doi: 10.1002/cncr.30262. Epub 2016 Aug 10.

47.

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.

Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM.

Cancer. 2016 Dec 1;122(23):3650-3656. doi: 10.1002/cncr.30231. Epub 2016 Aug 1.

48.

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M.

Am J Hematol. 2016 Dec;91(12):1221-1226. doi: 10.1002/ajh.24500. Epub 2016 Aug 29.

49.

Effects of surface materials on polarimetric-thermal measurements: applications to face recognition.

Short NJ, Yuffa AJ, Videen G, Hu S.

Appl Opt. 2016 Jul 1;55(19):5226-33. doi: 10.1364/AO.55.005226.

PMID:
27409214
50.

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F.

Blood. 2016 Jul 28;128(4):504-7. doi: 10.1182/blood-2016-03-707562. Epub 2016 May 27.

Supplemental Content

Loading ...
Support Center